2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
164
Breast Neoplasms
111
Colorectal Neoplasms
77
Neoplasms
65
Lung Neoplasms
61
Pancreatic Neoplasms
56
Stomach Neoplasms
52
Neoplasm Metastasis
51
Ovarian Neoplasms
45
Rectal Neoplasms
43
Esophageal Squamous Cell Carcinoma
38
Esophageal Neoplasms
38
Head and Neck Neoplasms
34
Squamous Cell Carcinoma of Head and Neck
32
Leukemia, Myeloid, Acute
32
Recurrence
26
Triple Negative Breast Neoplasms
25
Small Cell Lung Carcinoma
24
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Glioblastoma
23
Colonic Neoplasms
23
Uterine Cervical Neoplasms
22
Nasopharyngeal Carcinoma
22
Lymphoma
21
Lymphoma, Non-Hodgkin
20
Fallopian Tube Neoplasms
20
Prostatic Neoplasms
17
Melanoma
17
Sarcoma
16
Leukemia
16
Interventions
Fulvestrant
10
Alpelisib
7
Everolimus
6
Cetuximab
6
Letrozole
4
serabelisib
3
ribociclib
3
pembrolizumab
3
palbociclib
3
duvelisib
3
berzosertib
3
Paclitaxel
3
PX-866
3
NVP-BKM120
3
Irinotecan
3
sapanisertib
2
parsaclisib
2
olaparib
2
binimetinib
2
Topotecan
2
Gemcitabine
2
Carboplatin
2
volagidemab
1
venetoclax
1
tivozanib
1
tipifarnib
1
tanezumab
1
talazoparib
1
sotorasib
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Drug Therapy
×
Clear all
NCT03386162
2022-11-28
SAFIR-PI3K
UNICANCER
Phase 2
Terminated
31 enrolled